New Bonjela formulation available for teething infants

Medsafe has released a statement about the reclassification of choline salicylate from May 2023.

Bonjela advises that it has already introduced a new Bonjela product to help soothe teething which does not contain choline salicylate and is not affected by the reclassification.

The new formulation of Bonjela for infants has been listed as a medical device with Medsafe and it is available to consumers now for infants aged over six months through supermarkets and pharmacies.

Bonjela has been a trusted partner helping parents manage their infants teething pain for many years. We take the health of our consumers very seriously and when used as directed, Bonjela containing choline salicylate is safe to use.

The Medsafe reclassification follows a recommendation from an expert committee concerned about the potential for unintentional over-treatment in infants. Misuse and overuse of choline salicylate can have serious consequences on the health and well-being of teething infants.

Bonjela has worked closely with Medsafe to ensure consumer safety is the number one priority. We agree that products containing choline salicylate should be made available in pharmacy where there is a pharmacist available to help emphasise to parents the importance of using these products as directed.

Bonjela advises consumers to always read the label and to use products strictly as directed. If symptoms persist, or they have other concerns, they should consult their healthcare professional.